Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 8—August 2004


Pharmacy Data for Tuberculosis Surveillance and Assessment of Patient Management

Deborah S. Yokoe*Comments to Author , Steven W. Coon†, Rachel Dokholyan‡, Michael C. Iannuzzi†, Timothy F. Jones§, Sarah Meredith¶, Marisa Moore#, Lynelle Phillips**, Wayne Ray¶, Stephanie Schech††, Deborah Shatin††, and Richard Platt*†‡‡
Author affiliations: *Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; †Henry Ford Health System, Detroit, Michigan, USA; ‡Harvard Pilgrim Health Care, Boston, Massachusetts, USA; §Tennessee Department of Health, Nashville, Tennessee, USA; ¶Center for Education and Research in Therapeutics and Vanderbilt University, Nashville, Tennessee, USA; #Centers for Disease Control and Prevention, Atlanta, Georgia, USA; **Missouri Department of Health and Senior Services, Jefferson City, Missouri, USA; ††Center for Health Care Policy and Evaluation, Minneapolis, Minnesota, USA; and; ‡‡HMO Research Network Center for Education and Research on Therapeutics, Boston, Massachusetts, USA

Main Article

Table 2

Reasons for meeting pharmacy screening criteria among persons without active tuberculosis (TB)

Reasons why non-TB cases met screening criteria Plan A (%) Plan B (%) Plan C (%) Total (%)
Suspected active TB, full course of therapy 7 (13) 0 8 (9) 15 (10)
Suspected active TB, empiric therapy discontinued 12 (22) 0 35 (38) 47 (31)
Treatment of latent TB infection 8 (14) 3 (43) 10 (11) 21 (14)
Other mycobacterial infections 26 (47) 4 (57) 33 (36) 63 (41)
Other or unknown 2 (4) 0 5 (5) 7 (4)
Total 55 7 91 153

Main Article